The nicotine patch has had a good run. Decades of shelf space at every pharmacy in America. Billions in sales. The doctor’s go-to quit option for thirty years. And you know what? It works, sort of. Six months out, 10% are still clean. The other 90% are back at it.
Then this landed: a randomized clinical trial, just out in JAMA Network Open, researchers at Johns Hopkins gave smokers one dose of psilocybin (magic mushroom compound) and 40.5% were still off cigarettes at the six-month mark. Six times the quit rate of the patch. One dose.
Let that number sit for a second.
What Actually Happened
The trial enrolled 82 adult smokers: average age 47, averaging about 16 cigarettes a day, with a median of six previous failed quit attempts. Not people halfheartedly trying. People who’d quit before and failed, on average six times.
Both groups went through 13 weeks of CBT for smoking cessation first. Same starting line. Then, at week five, the designated quit date, one group received a single high dose of psilocybin (30 mg/70 kg, for those keeping score). The other group started an 8-to-10-week nicotine patch regimen per standard FDA labeling.
Six-month results, verified biochemically (breath CO, urinary cotinine; they didn’t take anyone’s word for it):
Psilocybin group: 40.5% prolonged abstinence. 52.4% abstinent in the prior seven days.
Nicotine patch group: 10% prolonged abstinence. 25% seven-day abstinence.
The psilocybin group also smoked roughly 50% fewer cigarettes per day between their quit date and the six-month follow-up. Even the relapsers smoked less.
The Science Behind the Session
Here’s what makes psilocybin genuinely weird, in the best possible way. It doesn’t interact with the nicotinic acetylcholine receptors that cigarettes hijack. It doesn’t suppress cravings the way varenicline (the active ingredient in Chantix) does. It doesn’t replace one delivery mechanism with another the way NRT (nicotine replacement therapy) does.
It works somewhere else entirely.
The researchers point to two things: a shift in how people see themselves, and greater psychological flexibility. Participants in the psilocybin group were encouraged beforehand to use the session to look hard at what smoking actually meant to them. During the session itself, typically eight to nine hours, lying on a couch with eyeshades, listening to a music program; many reported profound shifts in how they related to their habit.
It’s a different model entirely. Not chemical substitution. Not behavioral conditioning drilled in over weeks. One experience: guided, intentional, monitored. That’s it. And it seems to rewire something between the person and their addiction.
The Bigger Picture
This is a pilot trial: 82 participants, unblinded, run over nearly a decade (data collected 2015 to 2023, with COVID gaps in between). The authors are clear about that. Larger, more diverse samples are needed. The study group skewed White, educated, and highly motivated, with a notable history of prior psychedelic use (64.6%, versus a national prevalence of roughly 14%).
None of that diminishes what the numbers show. This story has more chapters to go.
And the bigger picture is hard to ignore: this is the same basic pharmacological class that’s showing promise for alcohol use disorder, opioid addiction, depression, and PTSD. Psilocybin doesn’t target one receptor system tied to one substance. The drug seems to reach something deeper: the higher-order psychological architecture through which addictive patterns take hold.
Eight million people die from tobacco-related causes every year worldwide. The patch isn’t cutting it. Neither is willpower, for most people. The question isn’t whether psychedelic-assisted therapy deserves a serious look from medicine at this point.
The question is how long it takes them to catch up.
Source: Johnson MW, Naudé GP, Hendricks PS, Garcia-Romeu A. “Psilocybin or Nicotine Patch for Smoking Cessation: A Pilot Randomized Clinical Trial.” JAMA Network Open. 2026;9(3):e260972.
Light up responsibly (and legally!)
